πŸš€ Pharmidex In Silico Drug Discovery – Step 4: Molecular Docking! πŸ”¬πŸ’»
February 26, 2025

Pharmidex continues advancing computational drug discovery! After identifying active/binding sites, our Molecular Docking step ensures precise interaction analysis between potential drug candidates and target proteins, streamlining lead optimization.


✨ Why is this step key?

βœ… Predicts binding affinity and stability of drug candidates

βœ… AI-enhanced docking for high-precision molecular interactions

βœ… Accelerates hit-to-lead identification with accurate simulations

βœ… Seamlessly integrates with the next in silico pipeline steps


By combining cutting-edge modeling and expert-driven analysis, we de-risk drug development and fast-track novel therapeutic discoveries.


πŸ“½οΈ Watch our latest video (3/5) showcasing how we refine drug-target interactions through Molecular Docking!


πŸ“© Let’s collaborate to transform drug discovery!


#DrugDiscovery #Pharmidex #AIinBiotech #MolecularDocking #PharmaceuticalInnovation

We’re Hiring! Senior/Principal Scientist–In Vivo Pharmacologist
July 30, 2025
We’re Hiring! Senior/Principal Scientist–In Vivo Pharmacologist
July 28, 2025
We’re delighted to welcome Gabrielle Georgiou and Dr. Mohammed Ahmad from the University of Hertfordshire as they begin their first experience in a scientific CRO environment here at Pharmidex ! This partnership is an exciting step in fostering early-career scientific talent by offering hands-on exposure to real-world drug discovery and preclinical research. A big thank you to the University of Hertfordshire for partnering with us to support the next generation of innovators. We’re proud to play a role in shaping future leaders in science through meaningful, practical learning opportunities. πŸ‘©‍πŸ”¬ πŸ‘¨‍πŸ”¬ Welcome to the team, Gabrielle and Mohammed!
BATA Taste Aversion
July 24, 2025
At Pharmidex , we offer Brief Access Taste Aversion (BATA) testing, which is a behavioural assay that quantifies how test subjects respond to different compounds or formulations by measuring lick response and aversion. This helps identify: βœ… Bitter-tasting APIs βœ… Unpalatable excipients βœ… The success of taste-masking strategies βœ… Formulation-dependent compliance risks Get in touch if you’re developing oral formulations, paediatric drugs, or repurposing bitter APIs, this could be the data your IND package needs.
More Posts